Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AGEN 2373

Next Previous
Search
Drug Profile

AGEN 2373

Alternative Names: AGEN-2373

Latest Information Update: 24 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agenus
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Malignant melanoma; Solid tumours

Most Recent Events

  • 24 Jan 2025 Agenus completes a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in US (NCT04121676)
  • 20 Jan 2025 Agenus plans a phase-I/II trial in Pancreatic cancer (First-line therapy, Adjuvant therapy, Neoadjuvant therapy) in USA in April 2025 (IV) (NCT06782932)
  • 05 Jun 2023 Interim adverse events and efficacy data from a phase I trial in Solid tumours released by Agenus

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top